Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Revenue of Vera Therapeutics, Inc. (VERA)
Revenue in 2023 (TTM): $1.86 M
According to Vera Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $1.86 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vera Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.86 M | $1.86 M | $-102,012,000 | $-95,989,000 | $-95,990,000 |
| 2022 | $ | $846 K | $-90,903,000 | $-89,055,000 | $-89,056,000 |
| 2021 | $ | $-176,000 | $-34,226,000 | $-32,608,000 | $-32,609,000 |
| 2020 | $ | $-251,000 | $-52,995,000 | $-53,412,000 | $-53,413,000 |
| 2019 | $ | $-509,000 | $-11,191,000 | $-11,853,000 | $-11,854,000 |